JP2021534182A5 - - Google Patents
Info
- Publication number
- JP2021534182A5 JP2021534182A5 JP2021507889A JP2021507889A JP2021534182A5 JP 2021534182 A5 JP2021534182 A5 JP 2021534182A5 JP 2021507889 A JP2021507889 A JP 2021507889A JP 2021507889 A JP2021507889 A JP 2021507889A JP 2021534182 A5 JP2021534182 A5 JP 2021534182A5
- Authority
- JP
- Japan
- Prior art keywords
- self
- composition according
- derived
- antigen
- immunogenic composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719219P | 2018-08-17 | 2018-08-17 | |
| US62/719,219 | 2018-08-17 | ||
| PCT/EP2019/072052 WO2020035609A2 (en) | 2018-08-17 | 2019-08-16 | Immunogenic compositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534182A JP2021534182A (ja) | 2021-12-09 |
| JP2021534182A5 true JP2021534182A5 (cg-RX-API-DMAC7.html) | 2022-08-22 |
Family
ID=67766133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507889A Pending JP2021534182A (ja) | 2018-08-17 | 2019-08-16 | 免疫原性組成物及びその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12083174B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3836963A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2021534182A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113164584A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019321186B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3109165A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020035609A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3727444A1 (en) | 2017-12-18 | 2020-10-28 | Intervet International B.V. | Swine influenza a virus vaccine |
| JP2023517644A (ja) | 2020-03-09 | 2023-04-26 | アークトゥラス・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン組成物及び方法 |
| JP2023521662A (ja) | 2020-04-03 | 2023-05-25 | グリットストーン バイオ インコーポレイテッド | 感染症抗原及びワクチン |
| IL298363A (en) * | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and uses thereof |
| EP4168044A1 (en) | 2020-06-19 | 2023-04-26 | Intervet International B.V. | Swine influenza a virus vaccine comprising two distinct rna replicon particles |
| US12178921B2 (en) | 2020-08-14 | 2024-12-31 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| MX2023004371A (es) | 2020-10-14 | 2023-07-26 | George Mason Res Foundation Inc | Lípidos ionizables, y métodos de fabricación y uso de los mismos. |
| AU2021392077A1 (en) * | 2020-12-02 | 2023-07-13 | Seqirus Inc. | Multicistronic rna vaccines and uses thereof |
| EP4313152A1 (en) * | 2021-03-26 | 2024-02-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
| US20240238404A1 (en) * | 2021-05-19 | 2024-07-18 | Daiichi Sankyo Company, Limited | Influenza virus nucleic acid lipid particle vaccine |
| AU2022396547A1 (en) * | 2021-11-29 | 2024-06-06 | Replicate Bioscience, Inc. | Methods of generating self-replicating rna molecules |
| WO2023213378A1 (en) * | 2022-05-02 | 2023-11-09 | BioNTech SE | Replicon compositions and methods of using same for the treatment of diseases |
| US20240009296A1 (en) * | 2022-07-10 | 2024-01-11 | Pfizer Inc. | Self-amplifying rna encoding an influenza virus antigen |
| TW202438672A (zh) * | 2023-01-31 | 2024-10-01 | 美商亞克圖羅斯醫療公司 | 四價流感疫苗之方法及組成物 |
| EP4661903A1 (en) * | 2023-02-09 | 2025-12-17 | Pfizer Inc. | Nucleic acids and uses thereof |
| WO2024254461A2 (en) * | 2023-06-07 | 2024-12-12 | Nutech Ventures | Methods and compositions for vaccine development and delivery |
| WO2024261648A1 (en) * | 2023-06-19 | 2024-12-26 | Seqirus Inc. | Multivalent subtype influenza vaccine |
| CN117205309B (zh) * | 2023-11-07 | 2024-02-02 | 今发制药(南京)有限公司 | 一种流感免疫原组合物和制备方法及其用途 |
| WO2025210141A1 (en) * | 2024-04-05 | 2025-10-09 | Boehringer Ingelheim Vetmedica Gmbh | Delivery system useful for topical administration of rna |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132418A (en) | 1980-02-29 | 1992-07-21 | University Patents, Inc. | Process for preparing polynucleotides |
| US4500707A (en) | 1980-02-29 | 1985-02-19 | University Patents, Inc. | Nucleosides useful in the preparation of polynucleotides |
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| US4668777A (en) | 1981-03-27 | 1987-05-26 | University Patents, Inc. | Phosphoramidite nucleoside compounds |
| US4973679A (en) | 1981-03-27 | 1990-11-27 | University Patents, Inc. | Process for oligonucleo tide synthesis using phosphormidite intermediates |
| US4373071A (en) | 1981-04-30 | 1983-02-08 | City Of Hope Research Institute | Solid-phase synthesis of polynucleotides |
| US5153319A (en) | 1986-03-31 | 1992-10-06 | University Patents, Inc. | Process for preparing polynucleotides |
| US5047524A (en) | 1988-12-21 | 1991-09-10 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5262530A (en) | 1988-12-21 | 1993-11-16 | Applied Biosystems, Inc. | Automated system for polynucleotide synthesis and purification |
| US5700642A (en) | 1995-05-22 | 1997-12-23 | Sri International | Oligonucleotide sizing using immobilized cleavable primers |
| PT1751289E (pt) | 2004-05-18 | 2009-03-31 | Alphavax Inc | Vectores de alfavirais derivados da tc-83, partículas e métodos |
| EP2451475A2 (en) * | 2009-07-06 | 2012-05-16 | Novartis AG | Self replicating rna molecules and uses thereof |
| WO2011076807A2 (en) | 2009-12-23 | 2011-06-30 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| FI4005592T3 (fi) | 2010-07-06 | 2023-01-13 | Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille | |
| CN103153284B (zh) | 2010-07-06 | 2015-11-25 | 诺华股份有限公司 | 含有其pKa值有利于RNA递送的脂质的脂质体 |
| US9192661B2 (en) | 2010-07-06 | 2015-11-24 | Novartis Ag | Delivery of self-replicating RNA using biodegradable polymer particles |
| CA2804591C (en) | 2010-07-06 | 2019-01-22 | Novartis Ag | Cationic oil-in-water emulsions |
| JP5911870B2 (ja) | 2010-08-31 | 2016-04-27 | ノバルティス アーゲー | 免疫原をコードするrnaの送達のためのpeg化リポソーム |
| RS63890B1 (sr) | 2010-08-31 | 2023-02-28 | Glaxosmithkline Biologicals Sa | Mali lipozomi za isporuku rnk koja kodira imunogen |
| EP3542789A3 (en) | 2010-08-31 | 2020-01-01 | GlaxoSmithKline Biologicals SA | Lipids suitable for liposomal delivery of protein-coding rna |
| US9636410B2 (en) | 2011-07-06 | 2017-05-02 | Glaxosmithkline Biologicals Sa | Cationic oil-in-water emulsions |
| RU2014104090A (ru) | 2011-07-06 | 2015-08-20 | Новартис Аг | Липосомы с эффективным соотношением n:p для доставки молекул phk |
| US11058762B2 (en) * | 2011-07-06 | 2021-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic compositions and uses thereof |
| US9655845B2 (en) * | 2011-07-06 | 2017-05-23 | Glaxosmithkline Biologicals, S.A. | Oil-in-water emulsions that contain nucleic acids |
| PT2750707T (pt) | 2011-08-31 | 2019-01-23 | Glaxosmithkline Biologicals Sa | Lipossomas peguilados para distribuição de arn que codifica imunogénio |
| BR112014008694A2 (pt) * | 2011-10-11 | 2017-06-20 | Novartis Ag | moléculas de ácido nucleico policistrônico recombinante |
| AU2014204826A1 (en) | 2013-01-10 | 2015-07-09 | Seqirus UK Limited | Influenza virus immunogenic compositions and uses thereof |
| ES2887254T3 (es) | 2013-03-08 | 2021-12-22 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| US10059655B2 (en) | 2013-12-19 | 2018-08-28 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| US10426737B2 (en) | 2013-12-19 | 2019-10-01 | Novartis Ag | Lipids and lipid compositions for the delivery of active agents |
| ES2969956T3 (es) | 2014-09-05 | 2024-05-23 | Novartis Ag | Lípidos y composiciones lipídicas para el suministro de agentes activos |
| US10022436B2 (en) * | 2016-01-11 | 2018-07-17 | Verndari, Inc. | Microneedle compositions and methods of using same |
| CN106822887A (zh) * | 2017-01-26 | 2017-06-13 | 中国科学院微生物研究所 | 一种流感病毒四价亚单位疫苗及其应用 |
-
2019
- 2019-08-16 AU AU2019321186A patent/AU2019321186B2/en active Active
- 2019-08-16 US US17/268,647 patent/US12083174B2/en active Active
- 2019-08-16 EP EP19758926.0A patent/EP3836963A2/en active Pending
- 2019-08-16 JP JP2021507889A patent/JP2021534182A/ja active Pending
- 2019-08-16 CN CN201980068212.4A patent/CN113164584A/zh active Pending
- 2019-08-16 CA CA3109165A patent/CA3109165A1/en active Pending
- 2019-08-16 WO PCT/EP2019/072052 patent/WO2020035609A2/en not_active Ceased
-
2024
- 2024-08-06 US US18/795,336 patent/US20250064916A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Park et al. | mRNA vaccines for COVID-19: what, why and how | |
| Lu et al. | The potential neurological effect of the COVID‐19 vaccines: a review | |
| JP2015522580A5 (cg-RX-API-DMAC7.html) | ||
| JP2014520807A5 (cg-RX-API-DMAC7.html) | ||
| JP2014522842A5 (cg-RX-API-DMAC7.html) | ||
| Mehraeen et al. | Vaccines for COVID-19: a systematic review of feasibility and effectiveness | |
| Simnani et al. | COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review | |
| JP2014520806A5 (cg-RX-API-DMAC7.html) | ||
| JP2023551982A5 (cg-RX-API-DMAC7.html) | ||
| EP3888676A1 (en) | Immunogenic combinations | |
| Lee et al. | Influenza viruses: innate immunity and mRNA vaccines | |
| HRP20230226T1 (hr) | Pegilirani liposomi za isporuku rna koja kodira imunogen | |
| JP2016539946A5 (cg-RX-API-DMAC7.html) | ||
| JP2019526580A5 (cg-RX-API-DMAC7.html) | ||
| KR20200111729A (ko) | 재조합 레플리콘 시스템을 이용한 면역 반응 유도 및 증진 | |
| JP2018514565A5 (cg-RX-API-DMAC7.html) | ||
| JP7403733B2 (ja) | インフルエンザhaスプリットワクチンの製造方法 | |
| US20250339511A1 (en) | Nucleic acid vaccine against monkeypox virus and use thereof | |
| JP2015524802A5 (cg-RX-API-DMAC7.html) | ||
| JP2014519817A5 (cg-RX-API-DMAC7.html) | ||
| CN101843901A (zh) | 以纳米乳剂为佐剂的流感病毒疫苗及其制备方法 | |
| Ftouh et al. | Contribution of nanotechnologies to vaccine development and drug delivery against respiratory viruses | |
| CN112294954B (zh) | 一种禽用佐剂组合物及其制备方法和应用 | |
| CN120379689A (zh) | 新型流感抗原 | |
| Wong et al. | COVID-19 Vaccine: Review of the Mechanism of Action of Different Types of Vaccine Li-Ann Wong*, Christina Gertrude Yap, Nowrozy Kamar Jahan, Naganathan Pillai. |